EHA 2020 – posters
Oncopeptides reports positive results from full data set of Phase 2 HORIZON trial in triple-class refractory multiple myeloma patients as well as several other posters during EHA. See posters below.
Documents
-
HORIZON Primary ePoster EHA 2020 - Dr Paul G RichardsonPDF, 0.6 MB
-
HORIZON TTNT ePoster EP1029 EHA 2020 - Dr Maria-Victoria MateosPDF, 0.6 MB
-
Melflufen Efficacy in MM with TP53 Aberrations ePoster EHA 2020 – Slipicevic et alPDF, 1.8 MB
-
BTZ-resistance EP915 Poster EHA 2020PDF, 1.1 MB
-
Aminopeptidase poster EHA 2020PDF, 3.1 MB